Pliaglis deal ends
Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities, announced that it has, by mutual agreement, terminated its commercialization and development license agreement with CROMA Pharma GmbH, that granted Croma exclusive rights to market Pliaglis in Germany, the United Kingdom, Ireland, Switzerland, Brazil, Romania, Belgium, the Netherlands and Luxembourg (the “Territories”).
Crescita Therapeutics Inc. a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities, announced that it has, by mutual agreement, terminated its commercialization and development license agreement with CROMA Pharma GmbH, that granted Croma exclusive rights to market Pliaglis in Germany, the United Kingdom, Ireland, Switzerland, Brazil, Romania, Belgium, the Netherlands and Luxembourg (the “Territories”).
Following a strategic business review, Croma decided to rationalize its product portfolio and realign its business priorities. Under the terms of the termination agreement, Crescita will regain all development and commercialization rights for Pliaglis in the Territories, and Croma will pay the Company €575,000 (approximately CAD$900,000). Crescita plans to explore potential new partnerships to commercialize Pliaglis in the Territories.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.